Ladies and gentlemen, thank you for standing by, and welcome to the Bavarian Nordic Q&A session. At this time, all participant lines are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star, then zero. I'd now like to hand the conference over to your speaker today, Mr. Rolf Sass . Please go ahead.
Thank you, and welcome to this conference regarding Bavarian Nordic's acquisition of two commercial vaccines from GSK. With me, I have our Chief Financial Officer Henrik Juul, as well as our President and CEO Paul Chaplin. Before we start, I need to read the forward-looking statements. This presentation includes forward-looking statements that involve risks, uncertainties, and other factors, many of which are outside our control, that could cause actual results to differ materially from the results discussed. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year, and financial preparedness as of year-end, as well as statements concerning our plans, objectives, goals, future events, performance that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements.
We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events, or circumstances after the date made, except as required by law. With this, I will hand back to you, to the operator, and open up for. Oh, sorry. I will hand it up to you, Paul.
Thanks, Rolf. Welcome everyone to the call. We're extremely excited to come out with the announcement today. I want to start actually by apologizing to our U.S. investors and analysts in that we didn't feel with such a large transformative deal that we could wait until this afternoon without informing the markets. The purpose of today's call is really to give everyone an opportunity for Q&A as the news sinks in. Just as a taster, you know, what we've done today is a truly transformative move. We've created a strong commercial independent company through acquiring two established products from GSK. These have combined revenues predicted or planned this year for EUR 175 million.
They're highly profitable with good margins, these products, together with JYNNEOS, our recently approved smallpox vaccine, is creating a leading infectious disease franchise that will accelerate Bavarian Nordic's pathway to profitability. We've had a vision since March, that in the next 5 years, we'll become a leading profitable vaccine company, which we've actually achieved today with this transaction, that's accelerated our vision by three years. The products that we're acquiring are using the same egg-based technology that we currently use to manufacture at JYNNEOS and all of our other products, there are significant synergies to unlock in the years ahead. As I said, these will be generating, together with JYNNEOS, a strong cash flow that will allow us to continue to invest in our promising and innovative pipeline.
We've truly transformed BN into a leading independent vaccine company, and the whole management here and all the employees are extremely excited. I know it's our task now to get that message across to all our investors and stakeholders. With that, I'll hand back to the operator and open up for Q&A.
As a reminder, to ask a question, please press star, then one on your telephone. To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Our first question comes from Chad Messer with Needham & Company. Your line is now open.
Great, thanks for taking my question. Going through your slide deck here, I apologize, I haven't heard what transpired on the other call, but I've looked through these slides. I'm most interested in your sort of sales and marketing strategy, which you kind of stated in the slides, you want to do a controlled and phased establishment of commercial infrastructure. Can you just expand on that a little further so we can get a better idea what Bavarian Nordic is gonna look like in, you know, 2020, 2021 and beyond?
Sure. Thanks, Chad Messer. Yes, let's put a little bit of flavor onto that. If we look at the two products, Rabipur and Encepur, currently there are limited marketing activities by GSK. As I said in the introduction, they're still pulling in EUR 175 million in revenues in 2019. For Rabipur, which is against rabies, it's basically emergency rooms, particularly in the U.S., where it's primarily used as a post-exposure, which needs limiting sales. In Europe, it's slightly different. It's more of travel clinics as a prophylactic for people traveling. Typically, the travel vaccine franchise, the sales and marketing efforts are nowhere near as large as traditional sales and marketing if you were selling directly to GPs. That's one thing.
We will take over sales and marketing immediately on closing or after closing, I should say, which will be January the first, anticipated. There we will have boots on the ground. It's also important to explain that for the two products, there are key markets. For Rabipur, it's really the U.S. and Germany that drives 80% of the planned EUR revenues. There, obviously, we'll have a key and strong focus and maybe rely on third parties to sell in other territories. For Encepur, a little bit different. The key markets, again, are Germany, which will be complementary to our activities for Rabipur and the Baltics and in the Nordics, where, again, quite limited sales force should allow us to secure those EUR revenues. We will have boots on the ground by the beginning of next year.
We are looking to bring in a highly experienced, chief commercial officer, who will join the executive management and drive those activities. We're very confident, actually, that these two products, given that they have very little marketing right now, gives us that chance to have time to build up those sales and marketing force, which will be more focused and dedicated than currently today.
All right, great. Thanks.
As a reminder, ladies and gentlemen, that is star, then one to ask a question. Again, ladies and gentlemen, that is Star, then one, if you'd like to ask a question at this time. I'm not showing any further phone questions at this time. I'd like to turn the call back to Mr. Chaplin for closing remarks.
Thank you. Well, thank you everyone for the time. Of course, if there are additional queries or questions that you have, you can contact Rolf or myself or Henrik. Thank you very much for taking the time. Appreciate your support. Have a great afternoon, everyone.
Ladies and gentlemen, this concludes today's conference call. Thank You for participating. You may now disconnect.